Ranzani, Otavio https://orcid.org/0000-0002-4677-6862
Martín Pérez, Carla https://orcid.org/0000-0002-9852-1976
Rubio, Rocío https://orcid.org/0000-0002-0448-3404
Ramírez-Morros, Anna https://orcid.org/0000-0001-8263-1292
Jimenez, Alfons https://orcid.org/0000-0003-0301-3344
Vidal, Marta
Canyelles, Mar https://orcid.org/0000-0002-3043-7612
Torres, Cèlia https://orcid.org/0000-0002-2521-4721
Barrios, Diana
Cuamba, Inocencia https://orcid.org/0000-0001-5964-0932
Santamaria, Pere https://orcid.org/0000-0003-3469-1586
Serra, Pau
Izquierdo, Luis https://orcid.org/0000-0002-3704-9874
Vidal-Alaball, Josep https://orcid.org/0000-0002-3527-4242
Molinos-Albert, Luis M. https://orcid.org/0000-0001-5447-6803
Aguilar, Ruth https://orcid.org/0000-0003-3277-3107
Ruiz-Comellas, Anna https://orcid.org/0000-0002-2848-2326
Moncunill, Gemma https://orcid.org/0000-0001-5105-9836
Dobaño, Carlota https://orcid.org/0000-0002-6751-4060
Funding for this research was provided by:
European Commission (101046314)
Fundació Privada Daniel Bravo Andreu
Article History
Received: 18 September 2024
Accepted: 3 December 2025
First Online: 13 December 2025
Competing interests
: P. Santamaria is founder, scientific officer and stockholder of Parvus Therapeutics and receives funding from the company. He also has a consulting agreement with Sanofi. The other authors declare no competing interests.